Open Access Highly Accessed Research article

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

Dimitrios Pectasides*, George Papaxoinis, Konstantine T Kalogeras, Anastasia G Eleftheraki, Ioannis Xanthakis, Thomas Makatsoris, Epaminondas Samantas, Ioannis Varthalitis, Pavlos Papakostas, Nikitas Nikitas, Christos N Papandreou, George Pentheroudakis, Eleni Timotheadou, Angelos Koutras, Joseph Sgouros, Dimitrios Bafaloukos, George Klouvas, Theofanis Economopoulos, Konstantinos N Syrigos and George Fountzilas

BMC Cancer 2012, 12:271  doi:10.1186/1471-2407-12-271

Article Metrics

6042
Total accesses


2
BioMed Central citations

Article metric FAQ

Accesses  

  • Last 30 days: 81 accesses
  • Last 365 days: 973 accesses
  • All time: 6042 accesses

These numbers are accesses on BioMed Central websites only, and an underestimate of total usage. More information

Cited by

BioMed Central: 2 citations